{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:02:15Z","timestamp":1788566535372,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.seminhematol.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T11:10:12Z","timestamp":1679915412000},"page":"80-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Report of consensus panel 2 from the 11th international workshop on Waldenstr\u00f6m's macroglobulinemia on the management of relapsed or refractory WM patients"],"prefix":"10.1053","volume":"60","author":[{"given":"S","family":"D'Sa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JV","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JJ","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MJ","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Leiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ML","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Talaulikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CS","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SK","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Tohidi-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Varettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JMI","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Garcia-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SP","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.003_bib0001","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2023.03.003_bib0002","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2023.03.003_bib0003","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.003_bib0004","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.003_bib0005","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.003_bib0006","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2023.03.003_bib0007","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2023.03.003_bib0008","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2023.03.003_bib0009","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstrom macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2023.03.003_bib0010","unstructured":"Meletios Dimopoulos, Editor Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia: a Biomarker Analysis of the ASPEN study comparing zanubrutinib and ibrutinib. IWWM11; 2022; Madrid."},{"key":"10.1053\/j.seminhematol.2023.03.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101682","article-title":"Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study","volume":"52","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.03.003_bib0012","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/cas.15344","article-title":"Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia","volume":"113","author":"Sekiguchi","year":"2022","journal-title":"Cancer Sci"},{"issue":"10277","key":"10.1053\/j.seminhematol.2023.03.003_bib0013","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.003_bib0014","first-page":"557","article-title":"Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed \/refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood (2022) 140 (Supplement 1): 557"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.003_bib0015","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1053\/j.seminhematol.2023.03.003_bib0016","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.003_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstrom macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.03.003_bib0018","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood-2022-155610","article-title":"Ibrutinib and venetoclax in previously untreated Waldenstr\u00f6m macroglobulinemia","volume":"140","author":"Castillo","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.003_bib0019","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.03.003_bib0020","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1002\/ajh.23985","article-title":"Cyclophosphamide, bortezomib, and dexamethasone combination in Waldenstrom macroglobulinemia","volume":"90","author":"Leblebjian","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.03.003_bib0021","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/jha2.597","article-title":"Bortezomib-based therapy is effective and well tolerated in frontline and multiply pre-treated Waldenstrom macroglobulinaemia including BTKi failures: a real-world analysis","volume":"3","author":"Khwaja","year":"2022","journal-title":"EJHaem"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.03.003_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.003_bib0023","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.21.00105","article-title":"Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia: final analysis of the Phase I\/II HOVON124\/ECWM-R2 study","volume":"40","author":"Kersten","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.03.003_bib0024","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1182\/blood-2022-165377","article-title":"phase II study of ibrutinib in combination with ixazomib in patients with Waldenstr\u00f6m macroglobulinemia (WM)","volume":"140","author":"Ailawadhi","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2023.03.003_bib0025","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstr\u00f6m macroglobulinemia: the lymphoma working party of the European group for blood and marrow transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.03.003_bib0026","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK inhibition impairs the innate response against fungal infection in patients with chronic lymphocytic leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2023.03.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100635","article-title":"Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections","volume":"40","author":"Maffei","year":"2020","journal-title":"Blood Rev"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.03.003_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/cells11061003","article-title":"BTK inhibitors impair platelet-mediated antifungal activity","volume":"11","author":"Nasillo","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1053\/j.seminhematol.2023.03.003_bib0029","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstrom's macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.03.003_bib0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.03.003_bib0031","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1016\/j.clml.2022.06.013","article-title":"R-CHOP Vs DA-EPOCH-R for double-expressor lymphoma: a University of California hematologic malignancies consortium retrospective analysis","volume":"22","author":"Othman","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.03.003_bib0032","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2021004926","article-title":"Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstrom macroglobulinemia","volume":"6","author":"Tahri","year":"2022","journal-title":"Blood Adv"},{"issue":"33","key":"10.1053\/j.seminhematol.2023.03.003_bib0033","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2009.27.3607","article-title":"Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the lymphoma working party of the European group for blood and marrow transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.03.003_bib0034","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2016.10.010","article-title":"Allogeneic transplantation for relapsed Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma","volume":"23","author":"Cornell","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.03.003_bib0035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3324\/haematol.2009.017814","article-title":"Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"95","author":"Garnier","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2023.03.003_bib0036","article-title":"Immunotherapy in indolent Non-Hodgkin's Lymphoma","volume":"17","author":"Amhaz","year":"2022","journal-title":"Leuk Res Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.03.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004128","article-title":"CD19-directed chimeric antigen receptor T cell therapy in Waldenstrom macroglobulinemia: a preclinical model and initial clinical experience","volume":"10","author":"Palomba","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2023.03.003_bib0038","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ajh.26807","article-title":"Survival trends in young patients with Waldenstrom macroglobulinemia: over five decades of experience","volume":"98","author":"Chohan","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.03.003_bib0039","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/bjh.18365","article-title":"Timing of referral to outpatient palliative care for patients with haematologic malignancies","volume":"198","author":"Patel","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:41Z","timestamp":1758522521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0037196323000252"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of consensus panel 2 from the 11th international workshop on Waldenstr\u00f6m's macroglobulinemia on the management of relapsed or refractory WM patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}